Xsolla Partners With iBLOXX to Promote Their Web3 Games Globally and Drive Launch of Upcoming Third-person Shooter Title StrayShot
11.12.2024 10:00:00 CET | Business Wire | Press release
iBLOXX Leverages Xsolla’s Monetization, Marketing, And Distribution Tools To Showcase Games Across MENA
Xsolla, a global video game commerce company, announces a new partnership with iBLOXX, a studio specializing in developing next-generation multiplayer games on the blockchain. The alliance was cultivated at the PGC Dubai event in April 2024, underscoring Xsolla’s continuous commitment to fostering long-term growth within the Middle East and Northern Africa region’s rapidly expanding gaming ecosystem.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241211854266/en/

(Graphic: Xsolla)
This strategic collaboration starts with supporting the launch of their new title, StrayShot. This thrilling third-person shooter game for PC and mobile allows players to step into the boots of a Bounty Hunter, ready to take on rivals in intense matches in several game modes. Players can team up with friends or go solo to fight other players in an epic battle for survival and earn exclusive rewards. This game is unique as it includes Web3 elements, NFTs, and tournaments, all of which Xsolla has solutions to support, particularly when it comes to subscription and virtual currency.
As a pivotal force within the MENA gaming ecosystem, Xsolla continues to leverage its advanced tools and platforms to empower partners and developers. Through this collaboration with iBLOXX, Xsolla is set to elevate the game studio’s reach and performance by providing key monetization, marketing, and distribution capabilities. Xsolla’s payments and monetization technology and expertise will ensure StrayShot gains maximum exposure while optimizing player engagement and revenue generation across multiple channels.
Chris Meredith, SVP EMEA at Xsolla, expressed his enthusiasm about the new partnership, commenting, “It’s great to work with a mature studio in the region with such a long-standing commitment to the growth and development in MENA,” he added. “This partnership will bring their groundbreaking titles and the launch of their newest title, StrayShot, to a wider audience, putting them firmly on the map as a major player in the industry.”
Domenik Maier, CEO of iBLOXX, stated: “We’re thrilled to join forces with Xsolla. Their support will be a game-changer for the upcoming launch of StrayShot, ensuring that it reaches a much larger, more engaged audience!”
The collaboration highlights Xsolla’s unwavering commitment to supporting long-term partnerships that contribute to the sustained growth and innovation of the regional gaming landscape. By partnering with iBLOXX, Xsolla is further enhancing its position in the MENA market, where gaming is experiencing rapid evolution and expansion.
For more information on Xsolla's partnership with iBLOXX to promote Web3 games globally and drive the launch of the upcoming third-person shooter StrayShot, visit xsolla.blog/xipw.
About Xsolla
Xsolla is a global video game commerce company with a robust and powerful set of tools and services designed specifically for the industry. Since its founding in 2005, Xsolla has helped thousands of game developers and publishers of all sizes fund, market, launch, and monetize their games globally and across multiple platforms. As an innovative leader in game commerce, Xsolla’s mission is to solve the inherent complexities of global distribution, marketing, and monetization to help our partners reach more geographies, generate more revenue, and create relationships with gamers worldwide. Headquartered and incorporated in Los Angeles, California, with offices in London, Berlin, Seoul, Beijing, Kuala Lumpur, Raleigh, Tokyo, Montreal, and cities around the world.
For additional information and to learn more, please visit xsolla.com.
About iBLOXX
iBLOXX is a leading innovator in Web3 gaming, leveraging its extensive background in decentralized technologies and quantitative finance to craft robust, player-driven game economies and deeply engaging virtual worlds. By blending cutting-edge blockchain infrastructure with innovative design principles, iBLOXX aims to deliver richer gaming experiences — where players truly own their in-game assets and game worlds evolve in tandem with their communities.
For additional information about their upcoming title StrayShot, please visit StrayShot.game.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241211854266/en/

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom